Fidelity Investments’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.4M | Buy |
154,867
+84,394
| +120% | +$11.2M | ﹤0.01% | 1776 |
|
|
2025
Q4 | $10M | Sell |
70,473
-1,868
| -3% | -$271K | ﹤0.01% | 2031 |
|
|
2025
Q3 | $10.2M | Sell |
72,341
-182,503
| -72% | -$24.7M | ﹤0.01% | 1994 |
|
|
2025
Q2 | $32M | Buy |
254,844
+158,926
| +166% | +$18.2M | ﹤0.01% | 1550 |
|
|
2025
Q1 | $10.6M | Sell |
95,918
-43,744
| -31% | -$5.54M | ﹤0.01% | 1889 |
|
|
2024
Q4 | $19.1M | Sell |
139,662
-106,444
| -43% | -$13.2M | ﹤0.01% | 1745 |
|
|
2024
Q3 | $28.4M | Sell |
246,106
-95,723
| -28% | -$13.1M | ﹤0.01% | 1589 |
|
|
2024
Q2 | $47.1M | Buy |
341,829
+109,310
| +47% | +$15M | ﹤0.01% | 1335 |
|
|
2024
Q1 | $32.1M | Sell |
232,519
-32,033
| -12% | -$4.37M | ﹤0.01% | 1488 |
|
|
2023
Q4 | $34.9M | Buy |
264,552
+242,547
| +1,102% | +$27.9M | ﹤0.01% | 1428 |
|
|
2023
Q3 | $2.48M | Buy |
22,005
+12,420
| +130% | +$1.31M | ﹤0.01% | 2233 |
|
|
2023
Q2 | $904K | Sell |
9,585
-22,990
| -71% | -$2.25M | ﹤0.01% | 2497 |
|
|
2023
Q1 | $3.3M | Sell |
32,575
-753,973
| -96% | -$78.5M | ﹤0.01% | 2231 |
|
|
2022
Q4 | $93.9M | Buy |
786,548
+443,868
| +130% | +$52M | 0.01% | 990 |
|
|
2022
Q3 | $36.4M | Buy |
342,680
+109,175
| +47% | +$11.1M | ﹤0.01% | 1371 |
|
|
2022
Q2 | $22.8M | Sell |
233,505
-6,156
| -3% | -$568K | ﹤0.01% | 1598 |
|
|
2022
Q1 | $22.5M | Sell |
239,661
-434,980
| -64% | -$36.9M | ﹤0.01% | 1729 |
|
|
2021
Q4 | $57.5M | Sell |
674,641
-2,790,506
| -81% | -$257M | ﹤0.01% | 1367 |
|
|
2021
Q3 | $332M | Sell |
3,465,147
-763,211
| -18% | -$72.1M | 0.03% | 591 |
|
|
2021
Q2 | $412M | Sell |
4,228,358
-2,873,730
| -40% | -$275M | 0.03% | 510 |
|
|
2021
Q1 | $691M | Sell |
7,102,088
-1,254,990
| -15% | -$132M | 0.06% | 317 |
|
|
2020
Q4 | $801M | Sell |
8,357,078
-346,668
| -4% | -$33.5M | 0.07% | 267 |
|
|
2020
Q3 | $837M | Buy |
8,703,746
+337,012
| +4% | +$39M | 0.08% | 212 |
|
|
2020
Q2 | $1.02B | Buy |
8,366,734
+1,083,313
| +15% | +$120M | 0.11% | 164 |
|
|
2020
Q1 | $630M | Sell |
7,283,421
-29,215
| -0.4% | -$2.86M | 0.09% | 208 |
|
|
2019
Q4 | $786M | Sell |
7,312,636
-1,316,144
| -15% | -$138M | 0.09% | 222 |
|
|
2019
Q3 | $778M | Sell |
8,628,780
-577,016
| -6% | -$53.9M | 0.09% | 212 |
|
|
2019
Q2 | $777M | Sell |
9,205,796
-1,231,257
| -12% | -$101M | 0.09% | 214 |
|
|
2019
Q1 | $920M | Sell |
10,437,053
-2,579,538
| -20% | -$216M | 0.11% | 176 |
|
|
2018
Q4 | $930M | Sell |
13,016,591
-473,255
| -4% | -$45.3M | 0.13% | 142 |
|
|
2018
Q3 | $1.66B | Buy |
13,489,846
+38,645
| +0.3% | +$4.38M | 0.19% | 94 |
|
|
2018
Q2 | $1.32B | Buy |
13,451,201
+60,325
| +0.5% | +$5.4M | 0.15% | 126 |
|
|
2018
Q1 | $1.11B | Buy |
13,390,876
+117,108
| +0.9% | +$9.89M | 0.13% | 153 |
|
|
2017
Q4 | $1.03B | Buy |
13,273,768
+40,738
| +0.3% | +$2.78M | 0.12% | 172 |
|
|
2017
Q3 | $811M | Buy |
13,233,030
+22,007
| +0.2% | +$1.16M | 0.1% | 212 |
|
|
2017
Q2 | $608M | Buy |
13,211,023
+1,180,874
| +10% | +$57.3M | 0.08% | 274 |
|
|
2017
Q1 | $521M | Sell |
12,030,149
-919,926
| -7% | -$39.4M | 0.07% | 310 |
|
|
2016
Q4 | $501M | Sell |
12,950,075
-51,727
| -0.4% | -$2.34M | 0.07% | 319 |
|
|
2016
Q3 | $658M | Buy |
13,001,802
+304,995
| +2% | +$15.2M | 0.09% | 244 |
|
|
2016
Q2 | $577M | Sell |
12,696,807
-270,800
| -2% | -$12.5M | 0.08% | 273 |
|
|
2016
Q1 | $513M | Buy |
12,967,607
+38,464
| +0.3% | +$1.53M | 0.07% | 286 |
|
|
2015
Q4 | $731M | Buy |
12,929,143
+48,165
| +0.4% | +$2.45M | 0.1% | 215 |
|
|
2015
Q3 | $513M | Buy |
12,880,978
+1,819,038
| +16% | +$87.9M | 0.07% | 292 |
|
|
2015
Q2 | $528M | Sell |
11,061,940
-828,214
| -7% | -$35.1M | 0.07% | 323 |
|
|
2015
Q1 | $472M | Buy |
11,890,154
+489,381
| +4% | +$17.5M | 0.06% | 366 |
|
|
2014
Q4 | $255M | Buy |
11,400,773
+12,863
| +0.1% | +$244K | 0.03% | 572 |
|
|
2014
Q3 | $178M | Buy |
11,387,910
+12,515
| +0.1% | +$187K | 0.02% | 700 |
|
|
2014
Q2 | $169M | Buy |
11,375,395
+76,809
| +0.7% | +$1.08M | 0.02% | 745 |
|
|
2014
Q1 | $182M | Buy |
11,298,586
+1,197,077
| +12% | +$20.5M | 0.03% | 687 |
|
|
2013
Q4 | $94.3M | Buy |
10,101,509
+42,167
| +0.4% | +$411K | 0.01% | 1011 |
|
|
2013
Q3 | $114M | Buy |
10,059,342
+600,130
| +6% | +$8.25M | 0.02% | 889 |
|
|
2013
Q2 | $127M | Buy |
+9,459,212
| New | +$116M | 0.02% | 804 |
|
Other funds holding NBIX
VPM
VCM
Fidelity Investments's NBIX Position: Q1 2026 in Review
Fidelity Investments increased its Neurocrine Biosciences (NBIX) stake by 120% in Q1 2026, buying an estimated $11.2M and bringing the position to 154,867 shares worth $20.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1776.
Fidelity Investments first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.66B in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Fidelity Investments held 154,867 shares of Neurocrine Biosciences worth $20.4M as of Q1 2026.
- Fidelity Investments bought 84,394 Neurocrine Biosciences shares in Q1 2026, an estimated $11.2M.
- Neurocrine Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #1776 holding.
- Fidelity Investments first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Fidelity Investments's Neurocrine Biosciences position peaked at $1.66B in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.